Cargando…

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

INTRODUCTION: Biological markers that reliably predict clinical or pathological response to primary systemic therapy early during a course of chemotherapy may have considerable clinical potential. This study evaluated changes in Ki-67 labeling index and apoptotic index (AI) before, during, and after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burcombe, Russell, Wilson, George D, Dowsett, Mitch, Khan, Ifty, Richman, Paul I, Daley, Frances, Detre, Simone, Makris, Andreas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557736/ https://www.ncbi.nlm.nih.gov/pubmed/16790076 http://dx.doi.org/10.1186/bcr1508

Ejemplares similares

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones
por: Parry, Suzanne, et al.
Publicado: (2021)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
por: Moazed, Vahid, et al.
Publicado: (2018)

Ki67 and breast cancer mortality in women with invasive breast cancer
por: Probert, Jake, et al.
Publicado: (2023)

Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer
por: Chen, Chunfa, et al.
Publicado: (2019)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
por: Liebscher, Sean C., et al.
Publicado: (2023)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling
por: Barricelli, Barbara Rita, et al.
Publicado: (2019)

Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer
por: LIN, QI, et al.
Publicado: (2013)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas
por: Menger, Richard, et al.
Publicado: (2017)

Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas
por: Ahmed, Shatha Th, et al.
Publicado: (2018)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
por: Bliss, Judith M., et al.
Publicado: (2023)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

The Ki67 index a prognostic marker in medullary thyroid carcinoma
por: Tisell, L E, et al.
Publicado: (2003)

IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation
por: Geread, Rokshana S., et al.
Publicado: (2019)

Prognostic Value of Ki-67 Index in Patients With Endometrial Stromal Sarcoma
por: Meng, Yu, et al.
Publicado: (2022)

Is Edema Zone Volume Associated With Ki-67 Index in Glioblastoma Patients?
por: Caramanti, Ricardo, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
por: Wu, Yu-tuan, et al.
Publicado: (2018)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
por: Pistelli, Mirco, et al.
Publicado: (2021)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions
por: Kubouchi, Koichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7kv7l42tupp64lf0iv26ffaj6s